A 68-year-old man with Parkinson's disease presents with severe resting tremor and rigidity that is inadequately controlled on levodopa monotherapy. He has no contraindications to anticholinergic agents. Which anticholinergic drug is the drug of choice for symptomatic relief of tremor and rigidity in this patient?

Explanation

## Anticholinergic Drugs in Parkinson's Disease **Key Point:** Benztropine is the drug of choice for symptomatic management of tremor and rigidity in Parkinson's disease, particularly when levodopa monotherapy is insufficient. ### Why Benztropine? **High-Yield:** Benztropine is a centrally-acting anticholinergic agent with the following advantages: - **Crosses blood-brain barrier** — essential for CNS effects in Parkinson's disease - **Selective CNS action** — minimal peripheral anticholinergic effects compared to atropine - **Rapid onset** — tremor relief within 15–30 minutes of parenteral administration - **Flexible dosing** — available in oral, IM, and IV formulations - **Synergistic with levodopa** — enhances motor symptom control without competing for absorption ### Mechanism in Parkinsonism In Parkinson's disease, there is relative excess of cholinergic activity in the basal ganglia due to dopamine deficiency. Anticholinergic agents restore the balance between dopaminergic and cholinergic neurotransmission, reducing tremor and rigidity (though less effective for bradykinesia). ### Comparative Table: Anticholinergic Agents | Drug | CNS Penetration | Primary Use | Onset | Route | | --- | --- | --- | --- | --- | | **Benztropine** | Excellent | Parkinsonism, dystonia | 15–30 min | PO, IM, IV | | Atropine | Poor | Anticholinergic toxin, bradycardia | Rapid | IV, IM | | Glycopyrrolate | None | Perioperative antisialagogue | Rapid | IV, IM | | Scopolamine | Moderate | Motion sickness, anesthesia | 30–60 min | Transdermal, IV | **Clinical Pearl:** Benztropine is preferred over atropine in Parkinson's disease because atropine is a tertiary amine that crosses the blood-brain barrier poorly and causes significant peripheral anticholinergic toxicity (tachycardia, mydriasis, urinary retention). ### Dosing in Parkinsonism - **Initial:** 0.5–1 mg once or twice daily (oral) - **Maintenance:** 1–2 mg daily in divided doses - **Acute dystonia:** 1–2 mg IM/IV for rapid relief **Warning:** Anticholinergic agents are less effective for bradykinesia and postural instability; they are primarily used for tremor and rigidity. Tolerance can develop with prolonged use.